4SC grants Maruho rights to KCNA3-targeted compounds
4SC AG (Xetra:VSC) granted Maruho Co. Ltd. (Osaka, Japan) exclusive, worldwide rights to a class of preclinical compounds targeting potassium channel Kv1.3 (KCNA3). 4SC will be eligible for up to €10...
BCIQ Target Profiles